Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1 Study to Characterize the Effects of Belzutifan on the Pharmacokinetics of a MATE1/2K Substrate, Metformin, in Healthy Adult Participants
Conditions
Interventions
Metformin
Belzutifan
Locations
1
United States
Celerion ( Site 0001)
Tempe, Arizona, United States
Start Date
August 18, 2025
Primary Completion Date
September 13, 2025
Completion Date
September 26, 2025
Last Updated
October 15, 2025
NCT06290258
NCT00090662
NCT06716502
NCT07310264
NCT07483606
NCT06342713
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions